Elegen Raises $35M in Series B Funding to Advance DNA Synthesis

Elegen Raises $35M in Series B Funding to Advance DNA Synthesis

AllegenA leading provider of DNA synthesis and production solutions announced the successful completion of a $35 million Series B funding round. The investment, led by Triatomic Capital, marks an important milestone in Allegiant's mission to revolutionize DNA synthesis technology.

Triatomic Capital was joined in the funding round by prominent investors such as GSK and John Ballantyne, co-founder of Aldevron, as well as existing investors including Andreessen Horowitz (a16z Bio+ Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures, and Agilent Technologies. Peter Zhao, general partner at Triatomic Capital, will also join Allegen's board, bringing valuable expertise and insight to the company.

The capital infusion will bolster Elegen's efforts to expand its ENFINIA™ DNA product line into clinical workflows, meeting the growing demand for GMP-compliant DNA in genetic medicine development. Leveraging its proprietary microfluidics approach, Elegen aims to accelerate the upstream discovery process and streamline the deployment of new medical procedures in industries such as agriculture, chemicals, healthcare and pharmaceuticals.

Founded in 2017 by Matthew Hill, Ph.D., and CEO, Elegen has emerged as a trailblazer in DNA synthesis technology, providing faster and more efficient solutions to meet the evolving needs of various industries. presents With a commitment to innovation and technological excellence, Elegen is well positioned to drive advances in DNA synthesis and contribute to the development of innovative genetic medicine.

“With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and to enable rapid and seamless deployment of new clinical approaches.”

As Allegan embarks on its next phase of growth and innovation, the company is dedicated to providing cutting-edge solutions that empower researchers and clinicians to unlock the full potential of genetic medicine.

About the Author

Leave a Reply